In This Issue
In Memoriam
Beneath the Blood Brain Barrier
The IASLC/ITMIG Thymic Malignancies Staging Project
Clinician Perceptions of Care Difficulty, Quality of Life, and Symptom Reports for Lung Cancer Patients
Therapy-Resistant Cancer Stem Cells Have Differing Sensitivity to Photon versus Proton Beam Radiation
Contributions of KRAS and RAL in Non–Small-Cell Lung Cancer Growth and Progression
Serpin B3 Is Associated with Poor Survival after Chemotherapy and Is a Potential Novel Predictive Biomarker in Advanced Non–Small-Cell Lung Cancer
A Phase 2 Randomized Trial of Paclitaxel and Carboplatin with or without Panitumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non–Small-Cell Lung Cancer
An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non–Small-Cell Lung Cancer
Long-Term Outcome after En Bloc Resection of Non–Small-Cell Lung Cancer Invading the Pulmonary Sulcus and Spine
Prognostic Validation of the Body Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity (BODE) Index in Inoperable Non–Small-Cell Lung Cancer
Prognostic Impact of Tumor Size Eliminating the Ground Glass Opacity Component
Esophageal Cancer Recurrence Patterns and Implications for Surveillance
Clinical Utility of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Staging of Patients with Potentially Resectable Esophageal Cancer
The Central Nervous System as a Sanctuary Site in ALK-Positive Non–Small-Cell Lung Cancer
Efficacy of First-Line Chemotherapy in Patients with Advanced Lung Sarcomatoid Carcinoma
Primary Salivary Gland–Type Lung Cancer
Unusual Migration of a Vena Cava Stent into the Pulmonary Artery Because of Tumor Reduction after Chemotherapy
Overexpression of EPH Receptor B2 in Malignant Mesothelioma Correlates with Oncogenic Behavior
Lung Adenocarcinoma Patient Refractory to Gefitinib and Responsive to Crizotinib, with Concurrent Rare Mutation of the Epidermal Growth Factor Receptor (L861Q) and Increased ALK/MET/ROS1 Gene Copy Number
An Uncommon Insertion Mutation in Exon 19 of EGFR Showed Stable Disease after TKI Treatment
Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry
Effective Crizotinib Schedule for Brain Metastases in ALK Rearrangement Metastatic Non–Small-Cell Lung Cancer
EGFR Mutation Testing for Squamous Cell Lung Carcinoma
Spectrum of EGFR Mutation in Lung Adenocarcinoma in Morocco
Spectrum of EGFR Mutation in Lung Adenocarcinoma in Morocco
To the Editor
In Response